The Rise of Blood-Brain-Barrier-Enabled Assets Infographic
This infographic Includes Insight Into:
- An inflection point for BBB-crossing technologies: Explore the delivery platforms shaping the next wave of CNS innovation.
- Rising disclosure of BBB data across modalities: A growing number of assets now report BBB penetration data, with notable activity across oligonucleotides, gene therapies, and antibodies.
- BBB-crossing strategies: Receptor-mediated transcytosis (RMT) is emerging as a leading approach for enabling BBB penetration. Here, we highlight where these strategies are being applied and how targets vary across CNS indications.
You May Also Be Interested In…
Learn More About Neuroscience
What is Beacon Neuroscience?
- The Most Comprehensive Way to Search the Neuroscience Drug Development Landscape: Unique search ontologies based on Neuroscience drug and trial characteristics
- Market Leading Approach to Neuroscience Preclinical & Clinical Data Curation: Manual curation of key Neuroscience research and development data points by Neuroscience research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Neuroscience company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
